JOHN VAETH: Open Payments
NPI 1992848345 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$465,679 in 578 payments from 8 companies in 2025. Trend: 2023 $408,796 · 2024 $411,634 · 2025 $465,679
Speaker / faculty: $261,496Honoraria: $106,425Travel & lodging: $82,814Food & beverage: $11,425Consulting: $3,520
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 206 | $155,917 |
| Axsome Therapeutics, Inc. | 167 | $128,273 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 124 | $112,455 |
| Vanda Pharmaceuticals Inc. | 63 | $50,875 |
| Otsuka America Pharmaceutical, Inc. | 14 | $18,056 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $60 |
| Tris Pharma Inc | 1 | $27 |
| Lundbeck LLC | 1 | $16 |
Products named: VRAYLAR, Auvelity, CAPLYTA, FANAPT, REXULTI, Dyanavel XR.
Industry payments across MD — which companies pay providers there.
